Vision Disorders: Clinical Trials

43 trials for Vision Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed. 43 Phase 2, 17 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 243Completed 43
Phase 117Completed 17
Phase 33Completed 3

Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders

Trials (filtered) newest first · largest first

All 43 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Iptacopan (LNP023), Placebo - Age-Related Macular Degeneration
Phase 2CompletedNovartis Pharmaceuticals1682022-02-172026-10-27
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Gene Therapy Product-MCO-010, Sham Injection - Retinitis Pigmentosa, Retinitis
Phase 2CompletedNanoscope Therapeutics Inc.272021-07-132024-03-22
Patient-centered Modular CBT for CPTSD: A Randomised Controlled Pilot Study
Psychotherapy - Complex Post-Traumatic Stress Disorder
Phase 1 / Phase 2CompletedDanish Veterans Centre602021-01-052025-04-02
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
NPI-001, Placebo - Usher Syndromes
Phase 1 / Phase 2CompletedNacuity Pharmaceuticals, Inc.492020-09-032026-07-01
ADVM-022 Intravitreal Gene Therapy for DME
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept - Diabetic Macular Edema, Diabetic Retinopathy
Phase 2CompletedAdverum Biotechnologies, Inc.362020-05-282025-07-10
Gene Therapy for Achromatopsia (CNGA3)
adeno-associated virus vector AAV- CNGA3 - Achromatopsia
Phase 1 / Phase 2CompletedMeiraGTx UK II Ltd112019-08-122022-12-01
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
LKA651, Lucentis - Diabetic Macular Edema
Phase 2CompletedNovartis Pharmaceuticals912019-05-242024-06-20
Acute Treatment Trial in Adult Subjects With Migraines
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System - Migraine
Phase 2 / Phase 3CompletedPfizer21542019-03-252023-09-25
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2
Phase 1 / Phase 2CompletedProQR Therapeutics202019-03-062022-04-20
Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome
Sodium Valproate 200Mg E/C Tablet, Sodium Valproate matched placebo - Wolfram Syndrome
Phase 2CompletedUniversity of Birmingham632018-12-282026-05-05
Side Effects of Atropine (SEA) Study
0.01% concentration atropine drops - Myopia
Phase 1 / Phase 2CompletedJeffrey J. Walline, OD PhD312018-07-232022-12-02
Gene Therapy for Achromatopsia (CNGB3)
AAV - CNGB3 - Achromatopsia
Phase 1 / Phase 2CompletedMeiraGTx UK II Ltd232017-01-162023-03-08
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus
Phase 1 / Phase 2CompletedWashington University School of Medicine212017-01-012024-03-13
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
AZD4017, Placebo - Idiopathic Intracranial Hypertension
Phase 2CompletedUniversity of Birmingham312014-04-252021-10-27
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
ELS-M11, Placebo - Migraine Headaches
Phase 1 / Phase 2CompletedAchelios Therapeutics482014-03-012017-07-11
Nitisinone for Type 1B Oculocutaneous Albinism
Nitisinone - Albinism, Vision Loss
Phase 1 / Phase 2CompletedNational Eye Institute (NEI)52013-04-162019-02-26
Revacept in Symptomatic Carotid Stenosis
Revacept, Placebo - Carotid Stenosis, Atherosclerosis
Phase 2CompletedAdvanceCor GmbH1582013-03-082021-01-28
Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study
verum tDCS, sham tDCS, VRT - Hemianopia, Stroke
Phase 1 / Phase 2CompletedUniversity of Magdeburg192013-03-012016-03-09
Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study
tDCS, Standard rehabilitation - Hemianopia, Stroke
Phase 1 / Phase 2CompletedUniversity of Magdeburg142013-01-012016-10-17
CNTF Implants for CNGB3 Achromatopsia
NT-501 CNTF-releasing implant - Eye Disease, Achromatopsia
Phase 1 / Phase 2CompletedNational Eye Institute (NEI)52012-07-012016-11-21

Showing 20 of 43. Sign in to see all of them.

Narrower conditions

Blindness (8)  ·  Amblyopia (5)  ·  Color Vision Defects (5)  ·  Macular Degeneration (5)  ·  Eye Diseases (4)  ·  Hemianopsia (4)  ·  Photophobia (4)  ·  Stroke (4)  ·  Geographic Atrophy (3)  ·  Retinal Diseases (3)  ·  Retinitis Pigmentosa (3)  ·  Usher Syndromes (3)  ·  Vision, Low (3)  ·  Wet Macular Degeneration (3)

Broader conditions

Nervous System Diseases (43)  ·  Neurologic Manifestations (43)  ·  Sensation Disorders (43)  ·  Pathological Conditions, Signs and Symptoms (42)  ·  Signs and Symptoms (42)  ·  Eye Diseases (39)  ·  Brain Diseases (15)  ·  Central Nervous System Diseases (15)  ·  Blindness (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Eye Diseases, Hereditary (10)  ·  Ear Diseases (9)  ·  Genetic Diseases, Inborn (9)  ·  Hearing Disorders (9)

Interventions

Ranibizumab (4)  ·  salicylhydroxamic acid (3)  ·  nitisinone (2)  ·  2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1)  ·  Acetaminophen (1)  ·  Acetazolamide (1)  ·  Aspirin (1)  ·  Atropine (1)  ·  Calcium Dobesilate (1)  ·  Ciliary Neurotrophic Factor (1)  ·  Codeine (1)  ·  Control Groups (1)  ·  Dantrolene (1)  ·  Dexamethasone (1)  ·  Electroconvulsive Therapy (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  University of Magdeburg (4)  ·  US Department of Veterans Affairs (3)  ·  MeiraGTx UK II Ltd (2)  ·  National Eye Institute (NEI) (2)  ·  Shahid Beheshti University of Medical Sciences (2)  ·  University of Birmingham (2)  ·  Achelios Therapeutics (1)  ·  AdvanceCor GmbH (1)  ·  Adverum Biotechnologies, Inc. (1)  ·  Asalus Medical Instruments Limited (1)  ·  Danish Veterans Centre (1)  ·  Jaeb Center for Health Research (1)  ·  Jeffrey J. Walline, OD PhD (1)  ·  Karolinska Institutet (1)

Countries

United States (26)  ·  United Kingdom (8)  ·  Germany (6)  ·  Canada (4)  ·  Puerto Rico (4)  ·  Spain (3)  ·  Austria (2)  ·  France (2)  ·  Iran (2)  ·  Australia (1)  ·  China (1)  ·  Denmark (1)  ·  Poland (1)  ·  Sweden (1)  ·  Turkey (Türkiye) (1)

Top investigators

Nancy Rocheleau, Program Analyst (3)  ·  John Fryer, Ph.D., Asst. Director (2)  ·  Agnes Wong, MD (1)  ·  Alan Lankford, PhD (1)  ·  Alan R. Spitzer, MD (1)  ·  Alexander Foss, BA BMBCh MRCP MRCOphth FRC (1)  ·  Alexandra Sinclair, MbChb PhD (1)  ·  Barbara J. Stoll, MD (1)  ·  Bernhard A Sabel, Ph.D. (1)  ·  Bernhard A Sabel, Prof. Dr. (1)  ·  Beverly S. Brozanski, MD (1)  ·  Brian P Brooks, M.D. (1)  ·  Charles C. Barr, MD (1)  ·  Craig A Elmets (1)

Results publications

PMID 37314061, PMID 10654946, PMID 20212198, PMID 20837811, PMID 23688108, PMID 24504128, PMID 24756302, PMID 24756514, PMID 24781936, PMID 25205868, PMID 25370510, PMID 25370513, PMID 25678831, PMID 26024112, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26934136, PMID 26951772, PMID 27694262, PMID 27978569, PMID 28082176, PMID 28130349, PMID 28492874, PMID 28923789, PMID 29800250, PMID 30674731, PMID 31215818, PMID 31592954, PMID 33098644, PMID 34185708, PMID 34219679, PMID 35129211, PMID 35695006, PMID 36240084, PMID 37172884, PMID 37418643, PMID 37740611, PMID 40010822

NIH funding

2018 (2), 2009 (1), 2016 (1), M01RR000054 (1), M01RR000070 (1), R21DK113487 (1), U10EY011751 (1), U10EY017281 (1), U10EY017387 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1)